SOLARA ACTIVE PHA SCI LTD

During the earnings conference call for Q1 FY27, management reported that Solara Active Pharma Sciences achieved revenues of INR 384 crores, reflecting a 20% year-on-year increase. EBITDA rose to INR 63.5 crores, up 10% year-on-year, while PAT reached INR 16.3 crores, marking a 55% increase year-on-year. Management highlighted strong performance in the base business, with revenues of INR 307 crores, a 24% year-on-year growth. Despite challenges in the Ibuprofen segment, which faced profitability issues, management noted a marginal sequential improvement. The company emphasized its commitment to operational efficiency and sustainable profitability growth, while also addressing the impact of geopolitical developments on raw material costs. Management expressed confidence in the long-term growth potential of the base business and thanked shareholders for their support.

Management emphasized strong financial performance and growth in the base business.